COPAXONE: Teva Initiates Phase III Study to Confirm Increased Efficacy of Higher Dose of Glatiramer Acetate for the Treatment of Relapsing-Remitting MS; Study to Confirm Phase II Results Showing Reduced Relapses and Lesions :
"Teva Pharmaceutical Industries (NASDAQ: TEVA) announced today the initiation of a large Phase III study designed to confirm the positive results from the Phase II study which compared a new higher dose of 40 mg/day dose of glatiramer acetate (GA) to the currently approved COPAXONE(R) (GA) 20 mg/day, whose efficacy and safety have been well established by three pivotal trials and over a decade of experience and clinical research. The study, called FORTE - FORTy mg Efficacy of glatiramer acetate - is beginning the enrollment of approximately 1,000 patients in 160 centers across North America, Europe, Argentina and Israel....."